157 related articles for article (PubMed ID: 35093383)
1. HBXIP is a novel regulator of the unfolded protein response that sustains tamoxifen resistance in ER+ breast cancer.
Zhang S; Wang R; Wang X; Guo X; Du Y; Guo X; Zong X; Zhu C; Zhou X
J Biol Chem; 2022 Mar; 298(3):101644. PubMed ID: 35093383
[TBL] [Abstract][Full Text] [Related]
2. Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer.
Liu B; Wang T; Wang H; Zhang L; Xu F; Fang R; Li L; Cai X; Wu Y; Zhang W; Ye L
J Hematol Oncol; 2018 Feb; 11(1):26. PubMed ID: 29471853
[TBL] [Abstract][Full Text] [Related]
3. Molecular signal networks and regulating mechanisms of the unfolded protein response.
Gong J; Wang XZ; Wang T; Chen JJ; Xie XY; Hu H; Yu F; Liu HL; Jiang XY; Fan HD
J Zhejiang Univ Sci B; 2017 Jan.; 18(1):1-14. PubMed ID: 28070992
[TBL] [Abstract][Full Text] [Related]
4. A novel chemical, STF-083010, reverses tamoxifen-related drug resistance in breast cancer by inhibiting IRE1/XBP1.
Ming J; Ruan S; Wang M; Ye D; Fan N; Meng Q; Tian B; Huang T
Oncotarget; 2015 Dec; 6(38):40692-703. PubMed ID: 26517687
[TBL] [Abstract][Full Text] [Related]
5. Estrogen Receptor and the Unfolded Protein Response: Double-Edged Swords in Therapy for Estrogen Receptor-Positive Breast Cancer.
Fan P; Jordan VC
Target Oncol; 2022 Mar; 17(2):111-124. PubMed ID: 35290592
[TBL] [Abstract][Full Text] [Related]
6. Anticipatory estrogen activation of the unfolded protein response is linked to cell proliferation and poor survival in estrogen receptor α-positive breast cancer.
Andruska N; Zheng X; Yang X; Helferich WG; Shapiro DJ
Oncogene; 2015 Jul; 34(29):3760-9. PubMed ID: 25263449
[TBL] [Abstract][Full Text] [Related]
7. Role of RBP2-Induced ER and IGF1R-ErbB Signaling in Tamoxifen Resistance in Breast Cancer.
Choi HJ; Joo HS; Won HY; Min KW; Kim HY; Son T; Oh YH; Lee JY; Kong G
J Natl Cancer Inst; 2018 Apr; 110(4):. PubMed ID: 29028222
[TBL] [Abstract][Full Text] [Related]
8. The oncoprotein HBXIP competitively binds KEAP1 to activate NRF2 and enhance breast cancer cell growth and metastasis.
Zhou XL; Zhu CY; Wu ZG; Guo X; Zou W
Oncogene; 2019 May; 38(21):4028-4046. PubMed ID: 30692632
[TBL] [Abstract][Full Text] [Related]
9. Oncoprotein HBXIP induces PKM2 via transcription factor E2F1 to promote cell proliferation in ER-positive breast cancer.
Liu BW; Wang TJ; Li LL; Zhang L; Liu YX; Feng JY; Wu Y; Xu FF; Zhang QS; Bao MZ; Zhang WY; Ye LH
Acta Pharmacol Sin; 2019 Apr; 40(4):530-538. PubMed ID: 29925919
[TBL] [Abstract][Full Text] [Related]
10. RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity.
Barua D; Sultana A; Islam MN; Cox F; Gupta A; Gupta S
BMC Cancer; 2023 Mar; 23(1):288. PubMed ID: 36997866
[TBL] [Abstract][Full Text] [Related]
11. A synthetic chalcone, 2'-hydroxy-2,3,5'-trimethoxychalcone triggers unfolded protein response-mediated apoptosis in breast cancer cells.
Lee DH; Jung Jung Y; Koh D; Lim Y; Lee YH; Shin SY
Cancer Lett; 2016 Mar; 372(1):1-9. PubMed ID: 26742460
[TBL] [Abstract][Full Text] [Related]
12. The unfolded protein response transducer IRE1α prevents ER stress-induced hepatic steatosis.
Zhang K; Wang S; Malhotra J; Hassler JR; Back SH; Wang G; Chang L; Xu W; Miao H; Leonardi R; Chen YE; Jackowski S; Kaufman RJ
EMBO J; 2011 Apr; 30(7):1357-75. PubMed ID: 21407177
[TBL] [Abstract][Full Text] [Related]
13. Heat Shock Protein 47 Maintains Cancer Cell Growth by Inhibiting the Unfolded Protein Response Transducer IRE1α.
Yoneda A; Sakai-Sawada K; Minomi K; Tamura Y
Mol Cancer Res; 2020 Jun; 18(6):847-858. PubMed ID: 32102897
[TBL] [Abstract][Full Text] [Related]
14. ERβ decreases breast cancer cell survival by regulating the IRE1/XBP-1 pathway.
Rajapaksa G; Nikolos F; Bado I; Clarke R; Gustafsson JÅ; Thomas C
Oncogene; 2015 Jul; 34(31):4130-41. PubMed ID: 25347741
[TBL] [Abstract][Full Text] [Related]
15. Targeting UPR branches, a potential strategy for enhancing efficacy of cancer chemotherapy.
Yu M; Lun J; Zhang H; Wang L; Zhang G; Zhang H; Fang J
Acta Biochim Biophys Sin (Shanghai); 2021 Nov; 53(11):1417-1427. PubMed ID: 34664059
[TBL] [Abstract][Full Text] [Related]
16. c-Src modulates estrogen-induced stress and apoptosis in estrogen-deprived breast cancer cells.
Fan P; Griffith OL; Agboke FA; Anur P; Zou X; McDaniel RE; Creswell K; Kim SH; Katzenellenbogen JA; Gray JW; Jordan VC
Cancer Res; 2013 Jul; 73(14):4510-20. PubMed ID: 23704208
[TBL] [Abstract][Full Text] [Related]
17. Reactivation of cAMP Pathway by PDE4D Inhibition Represents a Novel Druggable Axis for Overcoming Tamoxifen Resistance in ER-positive Breast Cancer.
Mishra RR; Belder N; Ansari SA; Kayhan M; Bal H; Raza U; Ersan PG; Tokat ÜM; Eyüpoğlu E; Saatci Ö; Jandaghi P; Wiemann S; Üner A; Cekic C; Riazalhosseini Y; Şahin Ö
Clin Cancer Res; 2018 Apr; 24(8):1987-2001. PubMed ID: 29386221
[No Abstract] [Full Text] [Related]
18. TXNIP Links Anticipatory Unfolded Protein Response to Estrogen Reprogramming Glucose Metabolism in Breast Cancer Cells.
Wang Y; Chen S
Endocrinology; 2022 Jan; 163(1):. PubMed ID: 34614512
[TBL] [Abstract][Full Text] [Related]
19. Oncoprotein HBXIP Modulates Abnormal Lipid Metabolism and Growth of Breast Cancer Cells by Activating the LXRs/SREBP-1c/FAS Signaling Cascade.
Zhao Y; Li H; Zhang Y; Li L; Fang R; Li Y; Liu Q; Zhang W; Qiu L; Liu F; Zhang X; Ye L
Cancer Res; 2016 Aug; 76(16):4696-707. PubMed ID: 26980761
[TBL] [Abstract][Full Text] [Related]
20. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
